Chromosomes in aggressive basal-like breast cancer (BLBC) cells are messy. Entire stretches vanish. Others get copied again and again. This chaos isn’t just background noise. It hides the actual switches that make the tumor grow. For years, scientists looked for those drivers in petri dishes. They found almost nothing.
Now, researchers in Toronto have changed the game. They found 81 new cancer-causing genes. They didn’t look at static cell cultures. They looked inside living animals.
The results, published in Nature, offer a clearer map of how abnormal chromosomes fuel BLBC. This is important because BLBC is hard to treat. It strikes younger women of color at disproportionate rates. It lacks the three common receptors—estrogen, progesterone, and HER2—that allow standard therapies to work. Without those targets, options are limited. Survival rates lag far behind other breast cancer subtypes.
How CRISPR-KOALA Finds What Cell Cultures Miss
To find these hidden drivers, the team needed a better tool. They started with CRISPR gene editing. But standard CRISPR only knocks genes out. It simulates deletion. That’s half the story.
BLBC cells don’t just lose genetic material. They gain it. Gene duplication increases activity. If you only study deletions, you miss half the picture. You miss the drivers that rely on being overactive.
Dr. Khalid Al-Zahrani and Dr. Daniel Schramek fixed this. They developed CRISPR-KOALA. This system can do both. It can silence genes. It can also switch them on. They applied this dual-function tool to living mouse mammary glands.
Why live models? Cell cultures simplify reality. They remove immune cells. They ignore blood vessels. They lack the fluctuating oxygen and nutrients of a real tumor. Cancer cells behave differently when surrounded by tissue.
“The reason we hadn’t found many of these-driving genes before is that we were working in cell culture models… Now that we can study this cancer directly in a living system, we can observe the biological intricacies.”
— Dr. Daniel Schramek
Why 90% of These Genes Stayed Hidden
The screening tested more than 3,700 candidate genes. These genes sit on chromosomes frequently altered in BLBC.
The results were stark. The researchers identified 81 genes previously unrecognized as cancer drivers.
Here is the kicker. Ninety percent of these 81 genes went undetected in standard lab dishes. Conventional methods failed them. They only appeared when the team tested them in the complex environment of a living animal.
This highlights a critical gap in cancer research. We’ve relied heavily on in vitro models. But aneuploidy—the state of having abnormal chromosome numbers—interacts with the body in ways dishes can’t replicate. The tumor microenvironment dictates which genes become vital. Without that context, you’re searching a crowded genetic neighborhood blindfolded.
PLGRKT: A Key Vulnerability for Treatment?
Among the 81 discoveries, one stood out. PLGRKT.
This gene acts as a powerful driver of BLBC growth. Its primary role? Survival in the dark.
Deep inside tumors, oxygen is scarce. Most cells starve without it. They rely on aerobic metabolism for efficient energy. PLGRKT helps cancer cells switch modes. It allows them to use backup metabolic processes. Essentially, it helps them scavenge energy when oxygen is low.
This isn’t just about keeping individual cells alive. It supports bulk tumor growth.
Identifying PLGRKT matters for precision therapy. BLBC patients need new options. Targeted therapies are scarce because the drivers are unknown. If PLGRKT is essential for survival in low-oxygen zones, blocking it could be a viable strategy. It’s a potential Achilles’ heel.
Moving Beyond the “Triple-Negative” Label
BLBC is often just called “triple-negative.” That label describes what the tumor doesn’t have. It doesn’t describe what drives it.
The 81 newly identified genes change that narrative. They provide concrete targets. They show how chromosomal chaos selects for specific genetic advantages.
The study combined computational analysis with functional genomics. It linked mouse models with human breast cancer data. Dr. Al-Zahrani notes that this combination uncovered roles for genes they didn’t know were involved.
This isn’t just an academic exercise. It’s a shift in perspective. We stop treating the “black box” of triple-negative cancer as an undifferentiated mass. We start seeing it as a landscape shaped by specific genetic gains and losses.
The tools are now in place. The genes are identified. The question is no longer just “what drives this cancer?” It’s “can we stop it?”
For now, the living tumor environment continues to whisper its secrets. We’re just finally learning how to listen.
